| Mental Retardation |
2021-006233-19: Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study |
|
|
| Not yet recruiting | 2 | 60 | Europe | COMP360, Capsule | COMPASS Pathfinder Limited, COMPASS Pathfinder Limited | Anorexia Nervosa (AN), Anorexia Nervosa (AN), Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-003834-34: Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia Estudio para evaluar la eficacia, la seguridad y la tolerabilidad del Luvadaxistat en pacientes con deterioro cognitivo asociado a la esquizofrenia |
|
|
| Ongoing | 2 | 308 | Europe | Luvadaxistat, NBI-1065844, Tablet | Neurocrine Biosciences, Inc., Neurocrine Biosciences, Inc. | Cognitive Impairment Associated With Schizophrenia Deterioro cognitivo asociado a la esquizofrenia, Cognitive Impairment and Schizophrenia Deterioro Cognitivo y Esquizofrenia, Psychiatry and Psychology [F] - Behavioral Disciplines and Activities [F04] | | | | |
NCT03775096: Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) |
|
|
| Recruiting | 2 | 15 | US | Carvedilol, Coreg | Michele Tagliati, MD | REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease | 08/24 | 08/24 | | |
2021-004927-34: Clinical study to investigate the efficacy, safety and tolerability of the test substance Ketamine hydrochloride prolonged release tablets compared to placebo in patients with treatment resistant depression. |
|
|
| Not yet recruiting | 2 | 180 | Europe, RoW | Ketamine Hydrochloride Prolonged Release Tablets, KET01, Prolonged-release tablet | Ketabon GmbH, Ketabon GmbH | Treatment-resistant depression, Treatment-resistant depression is defined as the intake of 2 different anti-depressant medications for a sufficient length of time at an adequate dose without an adequate improvement of the depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Recruiting | 2 | 80 | Canada | Celecoxib, MINT-CELECOXIB, NDC Code: 0025-1525, ATC Code: M01AH01, Canadian DIN: 02412497, Placebo | University of British Columbia, BC Children's Hospital Research Institute, Obsessive Compulsive Foundation | Obsessive-Compulsive Disorder, Pediatric Psychiatric Disorder | 06/23 | 06/23 | | |
2022-000054-28: Combining Clemastine and Aerobic Exercise to Treat Cognitive Dysfunction in Schizophrenia by Targeting Myelin Plasticity (OligoTreat) Die Behandlung der kognitiven Dysfunktion durch Verbesserung der Myelinplastizität mittels Kombination von Clemastin und aerobem Ausdauertraining bei Patienten mit einer Schizophrenie (OligoTreat) |
|
|
| Not yet recruiting | 2 | 90 | Europe | Clemastinfumarat, Tablet | Klinikum der Universität München, Stanley Foundation | Schizophrenia Schizophrenie, Schizophrenia Schizophrenie, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2022-003743-10: Study to Evaluate the Efficacy and Safety of Intranasal BPL-003 in Patients with Treatment Resistant Depression |
|
|
| Not yet recruiting | 2 | 225 | Europe | 5-MeO-DMT.Benzoate Dry Powder, BPL-003, Nasal powder in single-dose container | Beckley Psytech Ltd., Beckley Psytech Ltd. | Treatment-Resistant Depression (TRD), Depression that has not improved with other treatments., Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
| Completed | 2 | 208 | RoW | 50 mg Cannabidiol (CBD), BodECS BioAbsorb(TM) capsule, Placebo, 100 mg Cannabidiol (CBD) | Bod Australia, Woolcock Institute of Medical Research | Sleep Disturbance, Insomnia, Insomnia Type; Sleep Disorder, Insomnia, Transient, Insomnia Due to Anxiety and Fear, Insomnia Due to Other Mental Disorder | 07/23 | 07/23 | | |
2020-003720-16: Study of efficacy and safety of MIJ821 in addition to comprehensive standard of care on the rapid reduction of symptoms of Major Depressive Disorder in subjects who have suicidal ideation with intent |
|
|
| Not yet recruiting | 2 | 195 | Europe | MIJ821, MIJ821, Powder for solution for injection/infusion | Novartis Pharma AG, Novartis Pharma AG | Major Depressive Disorder with suicidal ideation with intent, Major Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
CLOZ-AID, NCT04529226: Study to Compare Clozapine vs Treatment as Usual in People With Intellectual Disability & Treatment-resistant Psychosis |
|
|
| Active, not recruiting | 2 | 75 | Europe | Clozapine, Nemex, Leponex, haloperidol, pimozide, olanzapine, risperidone, amisulpride | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | Psychosis, Intellectual Disability | 01/25 | 12/25 | | |
NCT05321498: Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation |
|
|
| Withdrawn | 2 | 60 | NA | XPro1595, INB03/XPro™, XENP1595, Dominant-negative Tumor Necrosis Factor (DN-TNF), Placebo, Matching Placebo | Inmune Bio, Inc. | Mild Cognitive Impairment (MCI), Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Mental Disorders | 10/23 | 10/23 | | |
| Completed | 2 | 275 | US | Common Elements Toolbox, COMET, Single-session intervention, Doing What Matters in Times of Stress: An Illustrated Guide, Self-help Plus, Guided self-help | Indiana University | Depression, Anxiety, Emotion Regulation | 05/23 | 09/23 | | |
NCT04937452: Dopaminergic Therapy for Frontotemporal Dementia Patients |
|
|
| Active, not recruiting | 2 | 75 | Europe | Rotigotine 4Mg/24Hrs Patch, Neupro, Rotigotine 6Mg/24Hrs Patch, Placebo | I.R.C.C.S. Fondazione Santa Lucia, Alzheimer's Drug Discovery Foundation | Frontotemporal Dementia, Dementia, Aphasia, Primary Progressive, Pick Disease of the Brain, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Neurocognitive Disorders, Mental Disorders, Neurodegenerative Diseases, Frontotemporal Lobar Degeneration, TDP-43 Proteinopathies, Proteostasis Deficiencies, Metabolic Disease, Aphasia, Speech Disorders, Language Disorders, Communication Disorders, Neurobehavioral Manifestations, Neurologic Manifestations | 12/23 | 04/24 | | |
NCT05554094: Psilocybin for the Treatment of Veterans With Post-Traumatic Stress Disorder |
|
|
| Recruiting | 2 | 15 | US | Psilocybin | Ohio State University | PTSD, Stress Disorders, Traumatic, Stress Disorders, Post-Traumatic, Trauma and Stressor Related Disorders, Mental Disorder | 01/25 | 07/25 | | |
NCT04821856: Evaluation of the Effectiveness of Cannabidiol in Treating Severe Behavioural Problems in Children and Adolescents With Intellectual Disability |
|
|
| Recruiting | 2 | 140 | RoW | Cannabidiol Oil, Placebo | Murdoch Childrens Research Institute, Monash University, University of Sydney, Deakin University | Intellectual Disability, Child Behavior Problem | 05/25 | 06/25 | | |
| Not yet recruiting | 2 | 180 | NA | TMS | Brigham and Women's Hospital, National Institutes of Health (NIH) | Major Depressive Disorder, Obsessive-Compulsive Disorder, Schizophrenia, Generalized Anxiety Disorder, Mood Disorders, Psychiatric Disorder, Mental Disorder, Depression, Anxiety | 06/29 | 06/30 | | |
| Not yet recruiting | 2 | 80 | US | Transcranial magnetic stimulation, Sham transcranial magnetic stimulation | Brigham and Women's Hospital | Anxiety Disorders, Mental Disorder, Psychiatric Disorder | 08/28 | 02/29 | | |
NCT05904717: Effect of PXS-4728A on Microglia Activation in Participants With Isolated Rapid Eye Movement Sleep Behaviour Disorder |
|
|
| Recruiting | 2 | 40 | Europe, RoW | PXS-4728 (A), Matching Placebo (B) | Pharmaxis | REM Sleep Behavior Disorder | 09/24 | 01/25 | | |
MINDFuL, NCT05318976: A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation |
|
|
| Recruiting | 2 | 201 | Europe, Canada, RoW | XPro1595, INB03/XPro™, XENP1595, DN-TNF, Placebo, Matching Placebo | Inmune Bio, Inc. | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Mild Cognitive Impairment | 12/24 | 12/24 | | |
NCT05838560: Dasatinib Plus Quercetin for Accelerated Aging in Mental Disorders |
|
|
| Recruiting | 2 | 40 | US | Dasatinib + quercetin | Washington University School of Medicine, UConn Health | Schizophrenia, Treatment Resistant Depression, Aging, Premature | 05/25 | 05/26 | | |
NCT05109364: Terazosin and Parkinson's Disease Extension Study |
|
|
| Recruiting | 2 | 15 | US | Terazosin therapy | Cedars-Sinai Medical Center | Symptomatic Parkinson Disease, REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease | 11/25 | 11/25 | | |
NCT04218968: Cardiac Changes in Early Parkinson's Disease: A Follow up Study |
|
|
| Enrolling by invitation | 2 | 15 | US | Carvedilol | Cedars-Sinai Medical Center | REM Sleep Behavior Disorder, Pre-motor Parkinson Disease, Symptomatic Parkinson Disease | 12/25 | 12/25 | | |
NCT04386317: Terazosin Effect on Cardiac Changes in Early Parkinson's Disease |
|
|
| Recruiting | 2 | 15 | US | Terazosin | Cedars-Sinai Medical Center | REM Sleep Behavior Disorder, Pre-motor Parkinson's Disease, Symptomatic Parkinson Disease | 12/25 | 12/25 | | |
NCT05522387: An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease |
|
|
| Active, not recruiting | 2 | 11 | RoW | XPro1595, INB03/XPro™, XENP1595, DN-TNF | Inmune Bio, Inc. | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 05/24 | 09/24 | | |
NCT03862950: A Trial of Metformin in Individuals With Fragile X Syndrome (Met) |
|
|
| Recruiting | 2 | 120 | Canada | Placebo Medication, Placebo, Metformin, Glumetza, Glucophage, Fortamet | University of Alberta, St. Justine's Hospital | Fragile X Syndrome, Fragile X Mental Retardation Syndrome, Mental Retardation, X-Linked, Genetic Diseases, X-Linked, Trinucleotide Repeat Expansion, Fra(X) Syndrome, Intellectual Disability, FXS, Neurobehavioral Manifestations, Sex Chromosome Disorders | 06/26 | 06/26 | | |
ANT, NCT05680727: Individualized Functional Connectivity Targeting in aiTBS for Depression |
|
|
| Recruiting | 2 | 40 | US | transcranial magnetic stimulation, TMS, theta burst stimulation, accelerated intermittent theta burst stimulation, aiTBS | Brigham and Women's Hospital | Depressive Disorder, Major, Depression, Mood Disorders, Mental Disorder, Psychiatric Disorder | 07/26 | 01/27 | | |
NCT04534023: A Clinical Study of the Efficacy of Idebenone in the Treatment of iRBD Into Synucleinopathies |
|
|
| Recruiting | 2 | 142 | RoW | Idebenone, Placebo | Ruijin Hospital, Second Affiliated Hospital of Soochow University, Wuhan Union Hospital, China | Rapid Eye Movement Sleep Behavior Disorder, Synucleinopathy | 09/26 | 09/26 | | |
OT-DEFI, NCT05864508: Interest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study. |
|
|
| Not yet recruiting | 2 | 30 | Europe | Oxytocin nasal spray | University Hospital, Toulouse | Autism Spectrum Disorder | 12/26 | 12/26 | | |
2012-004579-37: Psilocybin as a model of psychotic illness Psilocybin jako model psychotického onemocnění |
|
|
| Ongoing | 1/2 | 40 | Europe | Psilocybin, THC-1143G, Capsule | National Institute of Mental Health, Internal Grant Agency of the Czech Ministry of Health | Inclusion criteria:a) Men and women at age between 28 and 65 years b) healthy volunteers with negative psychiatric history (severe mental illnesses that meet the criteria of ICD 10 F0.X - F99.X) c) negative family psychiatric history in terms of psychoses up to 2nd generation of relatives Výběrová kritéria:a) Muži a ženy ve věku mezi 28 a 65 letyb) Zdraví dobrovolníci s negativní psychiatrickou anamnézou (závažná duševní onemocnění splňující kriteria MKN 10 F0.X - F99.X)c) Negativní rodinná psychiatrická anamnéza z hlediska psychóz až do příbuzných 2. Stupně, 1. Healthy volunteers without any psychiatric disorder2. Siblings, parents and grandparents must not experience schizophrenia or any other psychosis in the present or in the past 1. Zdraví dobrovolníci bez psychiatrického onemocnění2. Sourozenci, rodiče a prarodiče nesměli prodělat schizofrenii ani jiný typ psychóz v současnosti ani v minulosti, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2009-009475-35: Lack of Empathy as a Symptom in various Psychiatric Disorders |
|
|
| Ongoing | 1/2 | 75 | Europe | oxytocin, RVG 03716, Syntocinon, Syntocinon | KARAKTER universitair centrum voor kinder- en jeudpsychiatrie | Autism Spectrum Disorder (Autism, Asperger\'s Syndrome)Conduct DisorderMild Mental Retardation | | | | |
| Not yet recruiting | 1/2 | 16 | Europe | GH001, Inhalation solution | Gh Research Limited, GH Research Limited | Treatment-resistant depression, Depression that has not responded sufficiently to previous treatment, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
2021-002604-12: The effect of ketamine on aesthetics and role for antidepressant effects Einfluss von Ketamin auf ästhetische Prozesse und Relevanz für antidepressive Effekte |
|
|
| Not yet recruiting | 1/2 | 65 | Europe | Ketamin hameln, 32265.00.00, Solution for injection/infusion, Ketamin-hameln | Medical University of Vienna, Medical University of Vienna, Interdisciplinary Cluster Project | Depression Depression, Depression Depression, Psychiatry and Psychology [F] - Mental Disorders [F03] | | | | |
NCT06003582: Co-production and Feasibility RCT of Intervention to Improve the Mental Health of Children With a Social Worker |
|
|
| Recruiting | 1/2 | 30 | Europe | Infant Parent Support | University of Glasgow, NSPCC, Glasgow City Council, London Borough of Bromley, University of Nottingham, Queen Mary University of London | Parent-Child Relations, Child Mental Disorder, Child Maltreatment | 11/23 | 11/23 | | |
NCT03675282: Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls |
|
|
| Completed | 1/2 | 82 | US | (11C)PE2I, PET Scan, Ioflupane, DaT scan | Weill Medical College of Cornell University, National Institute of Neurological Disorders and Stroke (NINDS) | Parkinson Disease, REM Sleep Behavior Disorder, Healthy | 04/24 | 04/24 | | |
NCT06458686: Effect of Vitamin D Supplementation on Mental Health: An Exploratory Study on A University Students Suffering From Vitamin D Deficiency |
|
|
| Not yet recruiting | 1/2 | 70 | NA | Vit D, Placebo | German University in Cairo, Prof. Mohamed Hassan Solayman, Clinical pharmacy Department, German University in Cairo, Prof. May Ahmed Shawki, Clinical Pharmacy Department, Ain Shams University, Egypt | Psychiatric Disorder | 06/26 | 09/26 | | |
